Zosano Pharma Corporation (NASDAQ:ZSAN) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.17) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.15) by $0.02, Bloomberg Earnings reports. During the same period in the prior year, the company posted ($0.54) earnings per share.
Zosano Pharma Corporation (ZSAN) opened at 0.85 on Friday. The firm has a 50-day moving average price of $1.28 and a 200-day moving average price of $1.58. Zosano Pharma Corporation has a 52-week low of $0.45 and a 52-week high of $3.54. The company’s market cap is $33.32 million.
COPYRIGHT VIOLATION NOTICE: “Zosano Pharma Corporation (NASDAQ:ZSAN) Releases Earnings Results, Misses Estimates By $0.02 EPS” was reported by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://www.com-unik.info/2017/08/12/zosano-pharma-corporation-nasdaqzsan-releases-earnings-results-misses-estimates-by-0-02-eps.html.
Separately, ValuEngine upgraded Zosano Pharma Corporation from a “strong sell” rating to a “sell” rating in a research report on Tuesday, June 6th.
In other Zosano Pharma Corporation news, CEO John Peter Walker bought 73,716 shares of the firm’s stock in a transaction on Thursday, May 25th. The shares were acquired at an average cost of $1.36 per share, for a total transaction of $100,253.76. Following the purchase, the chief executive officer now directly owns 169,344 shares of the company’s stock, valued at $230,307.84. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Georgia Erbez bought 68,000 shares of the firm’s stock in a transaction on Thursday, May 25th. The stock was acquired at an average price of $1.32 per share, for a total transaction of $89,760.00. Following the completion of the purchase, the chief financial officer now directly owns 115,750 shares in the company, valued at $152,790. The disclosure for this purchase can be found here. 2.95% of the stock is owned by corporate insiders.
Institutional investors have recently made changes to their positions in the company. Northern Trust Corp raised its position in shares of Zosano Pharma Corporation by 591.4% in the second quarter. Northern Trust Corp now owns 79,234 shares of the biotechnology company’s stock worth $112,000 after buying an additional 67,774 shares in the last quarter. Granite Point Capital Management L.P. acquired a new position in shares of Zosano Pharma Corporation during the first quarter worth $285,000. Vanguard Group Inc. raised its position in shares of Zosano Pharma Corporation by 20.8% in the second quarter. Vanguard Group Inc. now owns 1,217,323 shares of the biotechnology company’s stock worth $1,716,000 after buying an additional 209,251 shares in the last quarter. Victory Capital Management Inc. acquired a new position in shares of Zosano Pharma Corporation during the first quarter worth $449,000. Finally, Nexthera Capital LP acquired a new position in shares of Zosano Pharma Corporation during the first quarter worth $950,000. Institutional investors and hedge funds own 24.03% of the company’s stock.
Zosano Pharma Corporation Company Profile
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.
What are top analysts saying about Zosano Pharma Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zosano Pharma Corporation and related companies.